21 reports

Gastric Cancer Testing, Treatment and Prevention: Technologies and Global Markets CHAPTER ## INTRODUCTION ## STUDY GOALS AND OBJECTIVES ## REASONS FOR DOING THE STUDY ## SCOPE AND FORMAT ## INTENDED AUDIENCE ## METHODOLOGY ## RELATED BCC RESEARCH REPORTS ## ANALYST' S CREDENTIALS ## BCC RESEARCH

  • Cancer
  • Gastric Cancer
  • Pathology
  • Therapy
  • World
  • Other cancers
  • Disease overview

Market outlook of the global gastric cancer drugs market Technavio’s market research analyst predicts the global gastric cancer drugs market to grow rapidly at a CAGR of approximately 8% during the forecast period. The presence of huge unmet needs in the market is expected to result in this market’s healthy growth during the forecast period....

  • Gastric Cancer
  • Eli Lilly & Co.
  • F. Hoffmann-La Roche Ltd.
  • Otsuka Pharmaceutical Co., Ltd.
  • Sanofi S.A.
  • Gastric Cancer Therapeutics Market, South Korea, Treatment Patterns ('000), 2015-2022
  • Gastric Cancer Therapeutics Market, China, Treatment Patterns ('000), 2015-2022

Translational Gastrointestinal Cancer; ##(##): ##-## Zhao Y, et al. (2015).

  • Gastric Cancer
  • World
  • Market Size
  • AstraZeneca PLC
  • Roche Group
  • SYMPTOMS OF GASTRIC CANCER
  • 3.1.1 Etiology

ITALIAN GASTROINTESTINAL TUMOR STUDY GROUP.

  • Gastric Cancer
  • Eli Lilly & Co.
  • Merck & Co., Inc.
  • Roche Group
  • Taiho Pharmaceutical Co., Ltd.

Gastric cancer

4546 5000 3864
  • Opdivo patient numbers for gastric cancer in Japan, 2015-24
  • GASTRIC CANCER HAS HIGH GLOBAL INCIDENCE AND MORTALITY RATES

Gastrointestinal Cancer Research, ##(##), ##-## < PMID> ##< / PMID>.

  • Gastric Cancer
  • East Asia
  • Japan
  • United States
  • Eli Lilly & Co.
  • 3.1 DISEASE BACKGROUND
  • 3.4.1 Sources Used

Natural Medicine Journal; ##(##).

  • Gastric Cancer
  • China
  • Japan
  • World
  • Forecast
  • SYMPTOMS OF GASTRIC CANCER
  • 3.1.1 Etiology

ITALIAN GASTROINTESTINAL TUMOR STUDY GROUP.

  • Gastric Cancer
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Roche Group
  • Taiho Pharmaceutical Co., Ltd.
  • SYMPTOMS OF GASTRIC CANCER
  • 3.1.1 Etiology

ITALIAN GASTROINTESTINAL TUMOR STUDY GROUP.

  • Gastric Cancer
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Roche Group
  • Taiho Pharmaceutical Co., Ltd.
  • SYMPTOMS OF GASTRIC CANCER
  • 3.1.1 Etiology

ITALIAN GASTROINTESTINAL TUMOR STUDY GROUP.

  • Gastric Cancer
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Roche Group
  • Taiho Pharmaceutical Co., Ltd.
  • SYMPTOMS OF GASTRIC CANCER
  • 3.1.1 Etiology

ITALIAN GASTROINTESTINAL TUMOR STUDY GROUP.

  • Gastric Cancer
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Roche Group
  • Taiho Pharmaceutical Co., Ltd.
  • Products under Development by Companies, H2 2017

Gastrointestinal events were predominantly grade ##/ ##, early in onset, and usually subsided within a month. ## DAS-I pts had grade ## pleural effusions; both had these events on prior DAS and were grade ## on study entry.

  • Cancer
  • Gastric Cancer
  • Targeted Therapy
  • Therapy
  • Pfizer Inc.
  • 04/20/2017: Five Prime to Present Clinical Data on FPA144 at 2017 ASCO Annual Meeting

Approximately ## patients with unresectable, locally advanced, or metastatic gastrointestinal cancer will be enrolled during the Phase ## portion of the FIGHT trial.

  • Gastric Cancer
  • Therapy
  • United States
  • Company
  • Five Prime Therapeutics, Inc.
  • MGD-007 - DRUG PROFILE
  • Phase I - Trial Details

A total of ## (## percent) patients developed AEs related to OPN-## all grade ## with gastrointestinal disorders being the most frequent (##. ## percent).

  • Gastric Cancer
  • Monoclonal Antibody
  • North America
  • United States
  • Product Initiative

Gastrointestinal events were predominantly grade ##/ ##, early in onset, and usually subsided within a month. ## DAS-I pts had grade ## pleural effusions; both had these events on prior DAS and were grade ## on study entry.

  • Gastric Cancer
  • Leukemia
  • Therapy
  • United States
  • Product Initiative
  • Clinical Trial profile. 66 Trial Title
  • 5. All the trials included are unique trials.

The prominent features of this report are - ##.

  • Clinical Trial
  • Gastric Cancer
  • Lung Cancer
  • World
  • Product Initiative
  • Clinical Trial profile. 1141 Trial Title
  • Clinical Trial profile. 1305 Trial Title

Platinum for Gastrointestinal Peritoneal Carcinomatosis Phase I Study of Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Escalating Dose I. P.

  • Clinical Trial
  • Drug Discovery And Development
  • Gastric Cancer
  • Therapy
  • World
  • DIFFERENT TYPES OF GASTRIC CANCER

The number of products in the pipeline targeting Pi##K/ mTOR/ AKT Inhibitor in 2015 was ##, while those targeting PD-##/ PDL-## Inhibitor were ##, and ## for VEGF inhibitor.

  • Gastric Cancer
  • United States
  • World
  • Market Size
  • Merck & Co., Inc.
  • GASTRIC CANCER - PIPELINE BY EDDINGPHARM INC
  • GASTRIC CANCER - PIPELINE BY GLYCONEX INC

ITS PIPELINE CANDIDATES ARE USED TO TREAT THE GASTROINTESTINAL AND CRC AND ORPHAN DISEASES.

  • Gastric Cancer
  • Monoclonal Antibody
  • Pharmaceutical
  • United States
  • Product Initiative

One cholangiocarcinoma patient demonstrated an ##% reduction in tumour size by Cycle ## and a complete resolution in one lesion by Cycle ##.

  • Gastric Cancer
  • Pharmaceutical
  • United States
  • World
  • ASLAN Pharmaceuticals Pte Ltd.
  • MGD-007 - DRUG PROFILE
  • CGX-1321 - DRUG PROFILE

A total of ## (## percent) patients developed AEs related to OPN-## all grade ## with gastrointestinal disorders being the most frequent (##. ## percent).

  • Gastric Cancer
  • Monoclonal Antibody
  • North America
  • United States
  • Product Initiative
  • Gastric Cancer, Programs Targeting FGFR 3
  • Gastric Cancer, Heatmap for First-Line Marketed Products

Gastrointestinal toxicities included nausea, vomiting, and diarrhea.

  • Cancer
  • Gastric Cancer
  • Pathology
  • United States
  • Deals & Alliance